BIOMAT Database Logo BIOMAT Database Logo

Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM). 2000

M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Service d'Hématologie, Hôpital Edouard Herriot, Lyon, France.

Although recurrent malignancy is the most frequent indication for second stem cell transplantation (2nd SCT), there are few reports that include sufficiently large numbers of patients to enable prognostic factor analysis. This retrospective study includes 150 patients who underwent a 2nd SCT for relapsed acute myeloblastic leukaemia (n = 61), acute lymphoblastic leukaemia (n = 47) or chronic myeloid leukaemia (n = 42) after a first allogeneic transplant (including 26 T-cell-depleted). The median interval between the first transplant and relapse, and between relapse and second transplant was 17 months and 5 months respectively. After the 2nd SCT, engraftment occurred in 93% of cases, 32% of patients developed acute graft-vs.-host disease (GVHD) >/= grade II and 38% chronic GVHD. The 5-year overall and disease-free survival were 32 +/- 8% and 30 +/- 8%, respectively, with a risk of relapse of 44 +/- 12% and a transplant-related mortality of 45 +/- 9%. In a multivariate analysis, five factors were associated with a better outcome after 2nd SCT: age < 16 years at second transplant; relapse occurring more than 12 months after the first transplant; transplantation from a female donor; absence of acute GVHD; and the occurrence of chronic GVHD. The best candidates for a second transplant are likely to be patients with acute leukaemia in remission before transplant, in whom the HLA-identical donor was female and who relapsed more than 1 year after the first transplant.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012008 Recurrence The return of a sign, symptom, or disease after a remission. Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006085 Graft Survival The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host. Graft Survivals,Survival, Graft,Survivals, Graft

Related Publications

M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
February 2011, British journal of haematology,
M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
November 2003, Bone marrow transplantation,
M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Société Française de Greffe de Moelle (SFGM).
May 1997, Bone marrow transplantation,
M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
March 2016, Bone marrow transplantation,
M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Hematopoietic Stem Cell Transplantation in Multiple Myeloma: A Retrospective Study of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
August 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,
M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM).
June 1997, British journal of haematology,
M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
June 1995, Bone marrow transplantation,
M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Allogeneic bone marrow transplantation remains an efficient consolidation for adults with acute myeloid leukemia even when performed very soon after diagnosis (< 100 days). The SFGM (Société Française de Greffe de Moelle.
June 1995, Leukemia,
M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Société Française de Greffe de Moelle.
February 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M Michallet, and M L Tanguy, and G Socié, and A Thiébaut, and A Belhabri, and N Milpied, and J Reiffers, and M Kuentz, and J Y Cahn, and D Blaise, and F Demeocq, and J P Jouet, and A S Michallet, and N Ifrah, and E Vilmer, and L Molina, and G Michel, and B Lioure, and M Cavazzana-Calvo, and J L Pico, and A Sadoun, and D Guyotat, and M Attal, and H Curé, and P Bordigoni, and L Sutton, and A Buzyn-Veil, and M Tilly, and N Keoirruer, and N Feguex
Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle.
July 1996, Blood,
Copied contents to your clipboard!